Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irofulven as First Line Therapy in Recurrent or Metastatic Gastric Cancer
NCT00062257Phase 2Completed
- Sponsor
- Cancer Therapeutics Research Group
- Start
- Jun 2003
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of irofulven in gastric cancer (GC), sponsored by Cancer Therapeutics Research Group. Primary endpoints: Objective Response Rate, Adverse Events and 1 more. Started Jun 2003; status: completed.
02
Drugs
irofulven
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT00062257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00062257.